Biosyent Inc
XTSX:RX

Watchlist Manager
Biosyent Inc Logo
Biosyent Inc
XTSX:RX
Watchlist
Price: 11.25 CAD 0.45% Market Closed
Market Cap: 132.7m CAD
Have any thoughts about
Biosyent Inc?
Write Note

Biosyent Inc
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Biosyent Inc
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Biosyent Inc
XTSX:RX
Long-Term Debt
CA$942.2k
CAGR 3-Years
-14%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bausch Health Companies Inc
TSX:BHC
Long-Term Debt
$21.1B
CAGR 3-Years
-2%
CAGR 5-Years
-2%
CAGR 10-Years
3%
Sundial Growers Inc
NASDAQ:SNDL
Long-Term Debt
CA$136.5m
CAGR 3-Years
415%
CAGR 5-Years
23%
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Long-Term Debt
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Long-Term Debt
$24.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
Curaleaf Holdings Inc
CNSX:CURA
Long-Term Debt
$884.9m
CAGR 3-Years
18%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Biosyent Inc
Glance View

Market Cap
130.3m CAD
Industry
Pharmaceuticals

BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. The company is headquartered in Mississauga, Ontario. BioSyent, through its wholly owned subsidiaries BioSyent Pharma Inc. (BioSyent Pharma) and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary of BioSyent, operates in the non-chemical insecticide business. BioSyent products include Combogesic, Aguettant System, Cathejell, Cysview, FeraMAX 150, FeraMAX Powder, Proktis-M, RepaGyn, and TIBELLA. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Aguettant System are used for a variety of injectable medications in hospitals and the acute care setting. FeraMAX 150 is an oral hematinic indicated for the prevention and treatment of iron deficiency anemia. RepaGyn for the healing of the vaginal mucosa and the treatment of vaginal dryness.

RX Intrinsic Value
9.51 CAD
Overvaluation 15%
Intrinsic Value
Price

See Also

What is Biosyent Inc's Long-Term Debt?
Long-Term Debt
942.2k CAD

Based on the financial report for Jun 30, 2024, Biosyent Inc's Long-Term Debt amounts to 942.2k CAD.

What is Biosyent Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 3Y
-14%

Over the last year, the Long-Term Debt growth was -17%. The average annual Long-Term Debt growth rates for Biosyent Inc have been -14% over the past three years .

Back to Top